Cerebrovascular, Cognitive and Cardiac Benefits of SGLT2 Inhibitors Therapy in Patients with Atrial Fibrillation and Type 2 Diabetes Mellitus: Results from a Global Federated Health Network Analysis

11Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

Abstract

Background: Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are effective anti-diabetic drugs improving cardiovascular outcomes in type 2 diabetes mellitus (T2DM) patients. This study investigated cardiovascular, cerebrovascular and cognitive outcomes of SGLT2i therapy in patients with atrial fibrillation (AF) and T2DM. Methods: Observational study using TriNetX, a global health research network of anonymised electronic medical records from real-world patients between January 2018 and December 2019. The network includes healthcare organisations globally but predominately in the United States. AF patients (ICD-10-CM code: I48) with T2DM were divided according to SGLT2i use or not, and balanced using propensity score matching (PSM). Patients were followed-up for 3-years. The primary endpoints were ischaemic stroke/transient ischemic attack (TIA), intracranial haemorrhage (ICH), and incident dementia. Secondary endpoints were incident heart failure and mortality. Results: We identified 89,356 AF patients with T2DM of which 5061 (5.7%) were taking a SGLT2i. After PSM, 5049 patients (mean age 66.7 ± 10.6 years; 28.9% female) were included in each group. At 3-years follow-up, the risk of ischaemic stroke/TIA was higher in patients not receiving SGLT2i (HR 1.12, 95% CI 1.01–1.24) and for ICH (HR 1.57, 95% CI 1.25–1.99) and incident dementia (HR 1.66, 95% CI 1.30–2.12). Incident heart failure (HR 1.50, 95% CI 1.34–1.68) and mortality (HR 1.77, 95% CI 1.58–1.99) risks were increased in AF patients not receiving SGLT2i. Conclusions: In our large ‘real world’ analysis of patients with concomitant AF and T2DM, SGLT2i reduced the risk of cerebrovascular events, incident dementia, heart failure and death.

References Powered by Scopus

Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes

9130Citations
N/AReaders
Get full text

Dapagliflozin in patients with heart failure and reduced ejection fraction

4677Citations
N/AReaders
Get full text

Dapagliflozin and cardiovascular outcomes in type 2 diabetes

4470Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Risk of osteoarthritis in patients with hidradenitis suppurativa: a global federated health network analysis

11Citations
N/AReaders
Get full text

Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies

10Citations
N/AReaders
Get full text

Sodium-glucose cotransporter-2 inhibitors and their potential role in dementia onset and cognitive function in patients with diabetes mellitus: a systematic review and meta-analysis

7Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Proietti, R., Rivera-Caravaca, J. M., López-Gálvez, R., Harrison, S. L., Marín, F., Underhill, P., … Lip, G. Y. H. (2023). Cerebrovascular, Cognitive and Cardiac Benefits of SGLT2 Inhibitors Therapy in Patients with Atrial Fibrillation and Type 2 Diabetes Mellitus: Results from a Global Federated Health Network Analysis. Journal of Clinical Medicine, 12(8). https://doi.org/10.3390/jcm12082814

Readers' Seniority

Tooltip

Professor / Associate Prof. 2

50%

Researcher 2

50%

Readers' Discipline

Tooltip

Medicine and Dentistry 4

67%

Nursing and Health Professions 2

33%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 4

Save time finding and organizing research with Mendeley

Sign up for free